

REMARKSRestriction Requirement:

In response to Examiner's restriction requirement, Applicants have cancelled Claims 2-5 and 20-31, without prejudice, and have elected to pursue the claims of Group I (i.e., Claims 1 and 6-19, drawn to a polypeptide and pharmaceutical compositions comprising the polypeptide, classified in Class 520, subclass 300).

Sequence Listing:

In response to the Examiner's request to comply with the requirements for patent applications containing nucleotide sequence and amino acid sequence disclosures, Applicants submit herewith a substitute computer readable form (CRF) of the Sequence Listing and a substitute paper copy of the Sequence Listing. The computer readable form and paper copy submitted herewith are the same, and introduce no new matter over what is disclosed in the application (37 C.F.R. 1.821(g)).

CONCLUSION

Any questions or discussion may be directed to the attorney named below, whose phone number is (510) 705-7901.

Respectfully submitted,

Dated: May 31, 2002

Melina A Shaw

Melissa A. Shaw, Reg. No. 38,301
Attorney for Applicants
Bayer Corporation
800 Dwight Way, P. O. Box 1986
Berkeley, CA 94701